1. Short title This Act may be cited as the Medical Marijuana Research Act of 2017 . 2. Production and supply (a) In general The Secretary of Health and Human Services— (1) until the date on which the Secretary determines that manufacturers and distributors (other than the Federal Government) can ensure a sufficient supply of marijuana for qualified marijuana researchers intended for medical research, shall— (A) continue to produce marijuana through the National Institute on Drug Abuse (NIDA) Drug Supply Program; and (B) offer for sale immature marijuana plants and the seeds of marijuana— (i) to all qualified marijuana researchers who submit a request for such plants or seeds to engage in research pursuant to the section 303(f)(3) of the Controlled Substances Act, as amended by section 3; and (ii) in quantities sufficient to produce an adequate supply of marijuana for such research; and (2) beyond the date specified in paragraph (1), may, at the Secretary’s discretion, continue to so produce and supply marijuana. (b) Requirement To verify registration Before supplying marijuana to any person through the National Institute on Drug Abuse Drug Supply Program, the Secretary of Health and Human Services shall— (1) require the person to submit documentation demonstrating that the person is a qualified marijuana researcher seeking to conduct research pursuant to section 303(f)(3) of the Controlled Substances Act, as amended by section 3; and (2) not later than 30 days after receipt of such documentation, review such documentation and verify that the marijuana will be used for such research (and for no other purpose authorized pursuant to this Act). (c) Guidelines on production The Commissioner of Food and Drugs, in consultation with the Director of the National Institute on Drug Abuse, shall— (1) not later than 180 days after the date of enactment of this Act, issue guidelines on the production of marijuana by qualified marijuana researchers pursuant to subsection (a)(1)(B)